1/9/2023 0 Comments Fit affinity![]() Rosetta atomistic modeling was used to estimate the stability, shape complementarity, and binding energy of the RBD. Based on multiple sequence alignments of over 200 ACE2 sequences, scientists detected several regions comprising the SARS-CoV-2 recognition site, which are not conserved.Ī total of 68 orthologous ACE2 genes were selected in this study. The long helical segment of ACE2 at the N-terminus formed the most potential receptor binding domain (RBD) recognition site. The construction of a potent ACE2-based immunoadhesin that remained effective against the original SARS-CoV-2 strain and VOCs was demonstrated in this study. Previous studies have indicated the efficacy of Arenacept, a potent immunoadhesin targeting Arenaviridae family viruses.Ī recent iSciencejournal study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs. Since zoonotic viruses tend to bind to animal-derived ortholog cellular receptors at a higher affinity compared to a human cell-surface receptor, immunoadhesins could be used as a superior anti-viral agent. These immune molecules are composed of an engineered binding domain fused to an Fc portion on an antibody. Immunoadhesins are antibody-like molecules and are a class of immunotherapeutic agents. However, reduced efficacy of mAb was reported against the Omicron variant. During the COVID-19 pandemic, several immunotherapeutic reagents, such as Etesevimab, Bamlanivimab, and Sotrovimab, based on mAbs were formulated. Additionally, animal models have exhibited efficacy in neutralizing mAbs against many viral infections, such as HIV-1, Lassa, Ebola, and SARS. Monoclonal antibodies (mAbs) are used for treating children with the respiratory syncytial virus. The main advantage of this therapy is its dual effect involving virus neutralization and clearance of infected cells by immune effector cells. Recently, targeted immunotherapy has proved to be a potential tool against viral diseases. Hence, there is an urgent need for effective therapeutic options to combat infection caused by Omicron and other emerging variants.Ĭompilation of the top interviews, articles, and news in the last year. The breakthrough infections have increased substantially as Omicron-related variants can evade immune protection induced by vaccines and natural infection. Image Credit: Adao/Shutterstock Backgroundĭespite COVID-19 vaccination, a large number of breakthrough infections has been reported where both vaccinated and SARS-CoV-2 convalescent individuals were re-infected. Study: Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. The B.1.1.529 (Omicron) variant, along with its subvariants (BA.4 and BA.5), have become the dominantly circulating strain worldwide. Due to genomic mutations, several SARS-CoV-2 variants have emerged, categorized as variants of concern (VOC) and variants of interest (VOI). ![]() The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed more than 6.5 million lives worldwide. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |